

When requesting Xeomin® (incobotulinumtoxinA), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines for the covered indications.

FDA-approved indications

Xeomin (incobotulinumtoxinA) is indicated for the treatment of

- Upper limb spasticity in adults
- Cervical dystonia in adults
- Blepharospasm in adults who were previously treated with Botox® (onabotulinumtoxinA)
- Chronic sialorrhea in adults

Coverage Guidelines

For all approved indications, the individual meets all of the following criteria:

- 18 years of age or older
- No infection at the proposed injection site
- Does not have a known hypersensitivity to the active substance botulin neurotoxin type A

For blepharospasm, an individual has been previously treated with onabotulinumtoxinA (Botox®)

Approval duration: 12 months

Dosing Recommendations

Blepharospasm- Same dose as previously used Botox®; if the dose is unknown use 1.25-2.5 units per injection site every 12 weeks. Mean number of injections per eye is 6. The total dose should not exceed 35 units/eye.

Cervical Dystonia- 120 units every 12 weeks

Upper Limb Spasticity- every 12 weeks

Muscle	Recommended dose (total dose [# of sites])
flexor digitorum superficialis or flexor digitorum profundus	25 to 100 units [2]
Flexor carpi radialis	25 to 100 units [1 or 2]
Flexor carpi ulnaris	20 to 100 units [1 or 2]

Brachioradialis	25 to 100 units [1 to 3]
Biceps	50 to 200 units [1 to 4]
Brachialis	25 to 100 units [1 to 2]
Pronator quadratus	10 to 50 units [1]
Pronator teres	25 to 75 units [1 or 2]
Flexor pollicis longus	10 to 50 units [1]
Adductor pollicis, flexor pollicis brevis, or opponens pollicis	5 to 30 units [1]

Chronic Sialorrhea-100 units every 16 weeks

References

1. Xeomin® (incobotulinumtoxinA) [prescribing information]. Raleigh, NC: Merz Pharmaceuticals, LLC: July 2018. Accessed July 6, 2018.
2. .Xeomin® (incobotulinumtoxinA). IN: DRUGDEX System Micromedex. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Updated July 10, 2018; Accessed July 19, 2018].
3. Simpson, D et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. American Academy of Neurology (2016) 86: 1818-1826.
4. Xeomin® (incobotulinumtoxinA). In: AHFS Drug Information Online Electronic Medical Library Bethesda, MD: American Society of Health-System Pharmacists. [Updated February 27, 2018; Accessed July 16, 2018].